Monthly Archives: March 2017

Binary Option Club Website Is Launched By Paul Schafer CEO Of BinaryOptionClub For Winning Binary Options Trading Signals

Binary Option Club Review – Binary Option Club Website By Paul Schafer CEO Of BinaryOptionClub has been released for Those who want reliable binary Options trading signals in binary trading industry can Download Binary Option Club Free

Dallas, United States – March 22, 2017 /MarketersMedia/

BinaryOptionClub Trading Website recently launched By Paul Schafer CEO Of BinaryOptionClub offers a concise description of the new binary options trading app developed by Paul Schafer. The price for the Binary Option Club Binary trading signal software download is zero. Understanding the binary options trading industry is a matter of extensive study and constant monitoring of the price action. Many people do not have the time or knowledge to follow all of the market moves. The Binary Option Club Binary trading app is a beneficial solution for such individuals, since the trading is done automatically, according to carefully identified algorithms and signals.

The initial release of the BinaryOptionClub software occurred in March, 2017 and has been receiving positive reviews since that time. The Binary Option Club APP download is easy to do and has no costs associated with the download. The Binary Option Club website offers additional bonuses which increase the value and effectiveness of the trading app. The bonuses are valued at more than $1000 and are also provided at no cost to the trader.

The Binary Option Club software app provides signals which are the notice to make a trade in the binary options market. Traders using the app may set it to make the trades automatically. The Binary Option Club Binary signals are based on proprietary algorithms which follow the movement of the prices in the trading marketplace. Binary options trading industry are designed to be a simple decision about upcoming market movement: either higher than the trade implementation price or lower than the price. The Binary Option Club results are determined quickly, sometimes in a matter of seconds.

Paul Schafer Founder Of BinaryOptionsClub Website has been trading binary options for about 11 years ago. Over the last three-plus years, he and his associates designed Binary Option Club software to become the go-to autotrading app for a thousand or beta testers traders using the new binary trading software. Because the Binary Option Club Binary software is designed for simplicity and ease of use, even those inexperienced with trading methods and definitions, can take advantage of the features.

Contact Info:
Name: Paul Schafer
Organization: Binary Option Club

Source URL: http://marketersmedia.com/binary-option-club-website-is-launched-by-paul-schafer-ceo-of-binaryoptionclub-for-winning-binary-options-trading-signals/180119

For more information, please visit http://www.thedailyhastings.com/reviews/binary-option-club-review-binary-option-club-software-scam

Source: MarketersMedia

Release ID: 180119

Global Dispersion Machine Market 2017 Size, Demand and Insights Analysis

RnRMarketResearch.com announces new research “2017 Deep Research Report on Global Dispersion Machine Industry” provided in its offerings.

March 22, 2017 /MarketersMedia/

Complete report on Dispersion Machine market spread across 122 pages, profiling 16 companies and supported with 139 tables and figures is now available @ http://www.rnrmarketresearch.com/global-dispersion-machine-market-research-report-2021-market-report.html .

The Global Dispersion Machine market 2017 research is a professional and in-depth study on the current state of the industry and provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Dispersion Machine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on Global major leading industry players of Dispersion Machine market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Dispersion Machine market development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 139 tables and figures helping analyze worldwide Dispersion Machine market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Companies profiled and studied for this Dispersion Machine market report include North America, Europe, China, Japan, Southeast Asia and India. Order a copy of Global Dispersion Machine Market Report 2017 @ http://www.rnrmarketresearch.com/contacts/purchase?rname=631823 .

Major Points from Table of Contents
1 Dispersion Machine Market Overview
2 Global Dispersion Machine Market Competition by Manufacturers
3 Global Dispersion Machine Production, Revenue (Value) by Region (2011-2017)
4 Global Dispersion Machine Supply (Production), Consumption, Export, Import by Regions (2011-2017)
5 Global Dispersion Machine Production, Revenue (Value), Price Trend by Type
6 Global Dispersion Machine Market Analysis by Application
7 Global Dispersion Machine Manufacturers Profiles/Analysis
8 Dispersion Machine Market Manufacturing Cost Analysis
9 Industrial Chain, Sourcing Strategy and Downstream Buyers
10 Marketing Strategy Analysis, Distributors/Traders
11 Market Effect Factors Analysis
12 Global Dispersion Machine Market Forecast (2017-2021)
13 Research Findings and Conclusion
14 Appendix
Author List
Disclosure Section
Research Methodology
Data Source

A discount can be asked before order a copy of Global Dispersion Machine Market Research Report @ http://www.rnrmarketresearch.com/contacts/discount?rname=631823 .

About Us:
Rnrmarketresearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.

Contact Info:
Name: Ritesh Tiwari
Email: sales@rnrmarketresearch.com
Organization: RnR Market Research

Source URL: http://marketersmedia.com/global-dispersion-machine-market-2017-size-demand-and-insights-analysis/180048

For more information, please visit http://www.rnrmarketresearch.com/global-dispersion-machine-market-research-report-2021-market-report.html

Source: MarketersMedia

Release ID: 180048

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trecora Resources – TREC

NEW YORK, NY / ACCESSWIRE / March 22, 2017 / Pomerantz LLP is investigating claims on behalf of investors of Trecora Resources (“Trecora” or the “Company”) (NYSE: TREC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Trecora and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On March 1, 2017, post-market, Trecora announced that the Company’s Audit Committee, “following consultation with management and discussion with the company’s independent registered public accounting firm…concluded that there were errors in the accounting for its equity in earnings from its investment in AMAK in Q2 and Q3 2016.” Trecora further advised investors that the Company’s quarterly reports for those periods should no longer be relied upon, and that Trecora would restate its financial and operating results for those quarters before filing its annual report for 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 457951

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Babcock & Wilcox and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / March 22, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Babcock & Wilcox (“Babcock” or the “Company”) (NYSE: BW). Investors, who purchased or otherwise acquired Babcock shares between February 19, 2013 and March 1, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 2, 2017 lead plaintiff deadline.

If you purchased shares of Babcock during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On March 1, 2017, Babcock & Wilcox revealed unsatisfactory fourth quarter 2016 outcomes, reporting “fourth quarter 2016 revenues of $380.0 million, a decrease of $122.7 million, or 24.4%, compared to the fourth quarter of 2015. GAAP earnings per share for the fourth quarter of 2016 were a loss of $1.47 compared to a loss per share of $0.10 for the fourth quarter of 2015.”

When this information was announced to the investing public, Babcock stock dropped, causing investors harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Khang & Khang LLP

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457949

INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against AmTrust Financial Services Inc., and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / March 22, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against AmTrust Financial Services Inc. (“AmTrust” or the “Company”) (NASDAQ: AFSI). Investors, who purchased or otherwise acquired AmTrust shares between May 10, 2016, and February 24, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 1, 2017 lead plaintiff deadline.

If you purchased shares of AmTrust during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On February 27, 2017, AmTrust stated that it “identified material weaknesses in its internal control over financial reporting that existed as of December 31, 2016, specifically related to ineffective assessment of the risks associated with the financial reporting, and an insufficient complement of corporate accounting and corporate financial reporting resources within the organization.” AmTrust will stall filing its 2016 financial statements.

When this information was announced to the investing public, AmTrust stock dropped, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457948

INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Northern Dynasty Minerals Ltd., and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / March 22, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Northern Dynasty Minerals Ltd. (“Northern Dynasty” or the “Company”) (NYSE MKT: NAK). Investors, who purchased or otherwise acquired shares between September 16, 2013 and February 14, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 17, 2017 lead plaintiff motion deadline.

If you purchased shares of Northern Dynasty during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On February 14, 2017, it was revealed that Northern Dynasty’s Pebble Project is not commercially viable, and that key partners have resigned from the project.

According to the Complaint, during the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: The Pebble Project held a negative net present value; that the Pebble Project is not commercially viable; and that due to the above, Northern Dynasty’s financial statements, as well as Defendants’ statements about Northern Dynasty’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

When this news was revealed to the investing public, the value of Northern Dynasty dropped, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457947

SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against USANA Health Sciences, Inc., and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / March 22, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE: USNA) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired shares between March 14, 2014 and February 7, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 14, 2017 lead plaintiff motion deadline.

If you purchased shares of USANA during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

USANA develops, manufactures, and sells nutritional and personal care products primarily to reduce the risk of chronic degenerative disease.

On February 7, 2017, USANA revealed that it will be starting an internal investigation of its Chinese subsidiary, BabyCare Ltd. (“BabyCare”).

In particular, the Company’s investigation concerns “compliance with the Foreign Corrupt Practices Act,” as well as “BabyCare’s expense reimbursement policies.”

When this information was revealed to the investing public, the value of USANA declined, causing investors harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457944

SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Global Eagle Entertainment Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Global Eagle Entertainment Inc. (“Global Eagle” or the “Company”) (NASDAQ: ENT). Investors, who purchased or otherwise acquired Global Eagle shares between November 9, 2016, and February 20, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 24, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

On February 21, 2017, Global Eagle announced that its CEO, Dave Davis, and CFO, Tom Severson, had both left the Company. Global Eagle also noted that it cannot file its 2016 annual report on time, and will withdraw its guidance for its 2016 financial performance. When this information was announced to the investing public, the value of Global Eagle declined, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457945

INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 22, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ: STML) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.

When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457942

Brisbane Ortho K Specialist Optometrists Myopia Hyperopia Presbyopia Treatment

Leading Brisbane orthokeratology optometrists, Brisbane Orthokeratology Specialists, re-launch their website uncovering optometry’s best kept secret – orthokeratology. Ortho-K provides clear unrestricted daytime vision without daytime contact lenses or glasses. Perfect treatment for myopia (myopia control), hyperopia, presbyopia and astigmatism. Particularly for sports and recreation.

Brisbane Ortho K Specialist Optometrists Myopia Hyperopia Presbyopia Treatment

Newstead, Australia – March 22, 2017 /PressCable/

Brisbane Orthokeratology Specialists have expanded their website highlighting the benefits of affordable orthokeratology or ortho k treatment for vision correction in Brisbane. Originally lifting the cloak off the fact that ortho k is optometry’s best kept secret when it comes to myopia (short-sightedness), myopia control and vision correction for sports and recreational activities. The site now includes specific information on how ortho k specialists can treat other vision conditions like hyperopia (far sightedness), presbyopia (reading glasses) and astigmatism. Discover the inside scoop on optometry’s best kept secret at https://brisbaneorthokeratologyspecialists.com.au

Orthokeratology, or ortho k, quite simply – no glasses, no daytime contact lenses, no surgery, just awesome vision. And the best part is it all happens while sleeping.

Ortho k, involves the use of special customized contact lenses, called ortho-k lenses, that are only worn overnight and gently correct the shape of the cornea. Specialist ortho k treatment results in clear unrestricted daytime vision.

Launching the expanded website Pat Gerry, a leading Brisbane specialist orthokeratology optometrist at Brisbane Orthokeratology Specialists, said “We want to give our patients options. With orthokeratology, they have a fresh new possibility. We want them to feel more confident and less frustrated – and in the case of myopia comfortable regarding its complications – by enabling them to have normal daytime vision without the inconvenience of glasses or daytime contact lenses. Live life without glasses Brisbane”.

The facts are that many people either dislike or hate wearing glasses or normal contact lenses for a variety of reasons – inconvenient, uncomfortable, restrictive, sometimes unsafe, fog up, misplacing them or breaking them. Yet the normal practice for most optometrists is to address this by offering various designer brand frames to help people feel better about having to wear glasses.

Surgery is an alternative but there are risks associated and the process is permanent and costly. Many people are unsure and uncertain with surgery or simply can’t afford it.

There is a very serious side to all of this with certain conditions like myopia or short-sightedness. A patient’s level of myopia is measured in dioptres and once this level exceeds -5.0 dioptres a person is classified with “high myopia”. A high myopia patient is at much greater risk of developing severe sight threatening diseases of the eyes like glaucoma, macular degeneration, cataracts, and retinal detachment. Parents of children with myopia should be aware that early intervention is crucial, as myopia progresses at a rapid rate, about -0.5 dioptres per year. That means an 8-year-old diagnosed a -1.0 dioptres would develop high myopia by the age of 16.

Orthokeratology has been proven in scientific studies to be extremely effective at slowing myopia progression and preventing the incidence of high myopia in 90% of patients.

Orthokeratology is a non-surgical, non-invasive and completely reversible so it can be performed on children aged 7 and above enabling the crucial early intervention so important for myopia control as well as adults. Orthokeratology treatment is also very affordable costing 70% less than LASIK eye-surgery which is ineffective for early intervention because it can’t be used until 18 years of age. Orthokeratology is also more cost effective compared to a lifetime of glasses or contact lenses that studies indicate add up to more than $25,000 for a person with myopia.

Orthokeratology is also effective for treating:

Presbyopia – where a person’s close vision deteriorates with age. The onset of this usually starts at about the age of forty and is a natural part of the aging process. Presbyopia makes vision difficult at a normal reading distance particularly in poor light and effects all sorts of close tasks such as reading, knitting, sewing and removing splinters. It may also mean difficulty concentrating when reading or periods of close work resulting in sore eyes, headaches or tiredness.

Hyperopia – far sightedness occurs when the eye is shorter than normal or the cornea (clear front window of the eye) is too flat. The result is that close objects focus behind the retina and will appear blurry. With significant hyperopia, vision can be blurry for objects at any distance, near or far. Some patients even experience double vision. Complications can include strabismus (crossed eyes) and amblyopia (lazy eye).

Astigmatism – caused by asymmetric imperfections in the shape of the cornea or lens resulting in images that focus in front of and beyond the retina, causing indistinct and asymmetric blurring of the vision for both close and distant objects. Every patient’s astigmatism is different but is probably best to compare it to looking into a fun house mirror in which objects appear too tall, too wide or too thin.

Pat Gerry, for Brisbane Orthokeratology Specialists, says: “Our aim is to bring top of mind awareness to orthokeratology and its effectiveness – vision correction a better way. There are so many people that aren’t aware of ortho k. It is the best kept secret in optometry and that simply doesn’t make any sense. Our expanded website fills this gap and now provides more information particularly related to treatment for myopia, hyperopia, presbyopia, astigmatism and correcting post LASIK-surgery. As we like to say no glasses, no daytime contact lenses, no surgery, just awesome vision”.

Discover more about Brisbane Orthokeratology Specialists and ortho k treatment for myopia control, hyperopia, presbyopia, astigmatism and vision correction for sports and recreation at https://brisbaneorthokeratologyspecialists.com.au.

Contact Info:
Name: Simon Hatherell
Email: info@brisbaneorthokeratologyspecialists.com.au
Organization: Brisbane Orthokeratology Specialists
Address: 1/3 Byres Street Newstead, Queensland 4006, Australia

For more information, please visit https://brisbaneorthokeratologyspecialists.com.au/

Source: PressCable

Release ID: 180015